Zevra Therapeutics
ZVRA
About: Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Employees: 59
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
52% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 29
17% more capital invested
Capital invested by funds: $271M [Q1] → $319M (+$47.3M) [Q2]
9% more funds holding
Funds holding: 109 [Q1] → 119 (+10) [Q2]
0.64% more ownership
Funds ownership: 65.5% [Q1] → 66.14% (+0.64%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]
14% less call options, than puts
Call options by funds: $5.02M | Put options by funds: $5.81M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
JMP Securities
Jason N. Butler
|
$18
|
Market Outperform
Maintained
|
13 Aug 2025 |
|
Cantor Fitzgerald
Kristen Kluska
|
$29
|
Overweight
Maintained
|
10 Jul 2025 |
|
HC Wainwright & Co.
Brandon Folkes
|
$26
|
Buy
Initiated
|
2 Jul 2025 |
Financial journalist opinion
Based on 3 articles about ZVRA published over the past 30 days
